Harvard Bioscience Approves Reverse Stock Split to Regain Compliance

Harvard Bioscience ( (HBIO) ) has shared an update.

Harvard Bioscience held a special shareholder meeting on March 6, 2026, at which investors approved a reverse stock split and a potential meeting adjournment to secure that vote. Following the approval, the board set a 1-for-10 split ratio and filed an amended charter in Delaware, reducing the number of outstanding shares from about 44.7 million to roughly 4.47 million while keeping authorized shares unchanged.

The reverse split will take legal effect at 4:30 p.m. Eastern on March 13, 2026, and the stock is expected to begin trading on a split-adjusted basis on Nasdaq under the existing HBIO ticker, but with a new CUSIP, on March 16, 2026. The move is intended to lift the company’s per-share trading price to regain compliance with Nasdaq’s minimum bid requirement, and will include cash in lieu of fractional shares and proportional adjustments to options, warrants and other convertible securities, affecting how both existing shareholders and equity holders are positioned going forward.

The most recent analyst rating on (HBIO) stock is a Hold with a $0.57 price target. To see the full list of analyst forecasts on Harvard Bioscience stock, see the HBIO Stock Forecast page.

Spark’s Take on HBIO Stock

According to Spark, TipRanks’ AI Analyst, HBIO is a Neutral.

The score is held down primarily by weak financial performance (declining revenue, ongoing losses, and higher leverage) and bearish technicals (below key moving averages with negative MACD). These are partially offset by improving cash flow and debt reduction, a more constructive earnings update with better margins/EBITDA, and corporate actions aimed at refinancing and future cost savings.

To see Spark’s full report on HBIO stock, click here.

More about Harvard Bioscience

Harvard Bioscience, Inc. is a global developer, manufacturer and seller of life science research tools that support fundamental research, drug and therapy discovery, bioproduction and preclinical testing. The company serves academic institutions, government labs, and leading pharmaceutical, biotechnology and contract research organizations worldwide through direct and distribution channels, with operations in the U.S., Europe and China.

Average Trading Volume: 458,120

Technical Sentiment Signal: Strong Sell

Current Market Cap: $25.54M

Learn more about HBIO stock on TipRanks’ Stock Analysis page.